Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-23
2011-08-23
Paras, Jr., Peter (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100
Reexamination Certificate
active
08003618
ABSTRACT:
Disclosed is an invention for focally modulating the activity of a calcium channel in a mammal. In one aspect, the invention features a method that includes contacting a pre-determined tissue or organ region with a nucleic acid sequence encoding a GEM protein or a variant thereof to express the GEM protein or variant within the region. Typical methods further include expressing the GEM protein or variant so as to modulate the activity of the calcium channel. The invention has a wide spectrum of useful applications including treating a medical condition associated with unsuitable calcium channel activity.
REFERENCES:
patent: 5163950 (1992-11-01), Pinchuck et al.
patent: 5436128 (1995-07-01), Harpold et al.
patent: 5662585 (1997-09-01), Willis et al.
patent: 5824550 (1998-10-01), Hruska et al.
patent: 5836905 (1998-11-01), Lemelson et al.
patent: 5944710 (1999-08-01), Dev et al.
patent: 5965396 (1999-10-01), Pan et al.
patent: 6086582 (2000-07-01), Altman et al.
patent: 6156726 (2000-12-01), Newcomb et al.
patent: 6207422 (2001-03-01), Brown et al.
patent: 6214620 (2001-04-01), Johns et al.
patent: 6309375 (2001-10-01), Glines et al.
patent: 6365337 (2002-04-01), Letts et al.
patent: 6605274 (2003-08-01), Dillmann et al.
patent: 6776987 (2004-08-01), Edelberg et al.
patent: 7122307 (2006-10-01), Rosen et al.
patent: 2002/0009772 (2002-01-01), Snutch
patent: 2002/0094326 (2002-07-01), Donahue et al.
patent: 2002/0155101 (2002-10-01), Donahue et al.
patent: 2002/0187949 (2002-12-01), Rosen et al.
patent: 2002/0188212 (2002-12-01), Rosen et al.
patent: 2003/0118988 (2003-06-01), Kandel et al.
patent: 2003/0195470 (2003-10-01), Ponzi
patent: 2004/0204376 (2004-10-01), Marban et al.
patent: 2004/0254134 (2004-12-01), Marban et al.
patent: 2005/0074850 (2005-04-01), Nadler et al.
patent: 2007/0042347 (2007-02-01), Rosen et al.
patent: 2009/0291068 (2009-11-01), Marban et al.
patent: 99/23880 (1990-05-01), None
patent: 96/28537 (1996-09-01), None
patent: 99/32615 (1999-07-01), None
patent: 00/18903 (2000-04-01), None
patent: 00/38518 (2000-07-01), None
patent: 00/41731 (2000-07-01), None
patent: 02/19966 (2002-03-01), None
patent: 02/33111 (2002-04-01), None
Concalves M, A concise peer into the background, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene repair, 2005, Gene Therapy, vol. 12, pp. 639-646.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Fishbein I, Site specific gene delivery in the cardiovascular system, 2005, J. Controlled Release, vol. 109, pp. 37-48.
Wright et al., 2001, Basic Res. Cardiol., vol. 96, pp. 227-236.
Beguin et al., 2001, Nature, vol. 411, pp. 701-706.
Lipscombe D., 2002, Circulation Res., vol. 90(9), pp. 981-987.
Elliott, 2001, Cell Calcium, vol. 30(2), pp. 72-93.
Krougliak et al., 2001, J Gene Med., vol. 3, pp. 51-58.
Li et al., 2001, Cancer Research, vol. 61, pp. 6428-6236.
Maguire et al., 1994, Science, vol. 265, pp. 241-244.
Finlin et al., 2000, Biochem J., vol. 347, pp. 223-231.
Liu et al., 2007, J. Gene Med., vol. 9, pp. 613-619.
Murata et al., 2004, Cir. Res., vol. 95, pp. 398-405.
Ballipejalli et al., 2004, Cir. Res., vol. 95, pp. 337-339.
Aresta, S. et al., “A Novel Rho GTPase-activating-protein interacts with Gem, a member of the Ras superfamily of GTPases,”Biochem. J., 2002, pp. 57-65. vol. 367.
Muth, James N. et al., “Use of transgenic mice to study voltage-dependent Ca2+channels,”Trends in Pharmacological Sciences, Oct. 2001, pp. 526-532. vol. 22. No. 10.
Dunlap, K. et al., “Exocytotic Ca2 +Channels in Mammalian Central Neurons,”Trends Neurosci., 1995, vol. 18. p. 89.
Fisher, R. et al.., “Calmodulin Binds to and Inhibits GTP Binding of the Ras-like GTPase Kir/Gem,”Journal Biology Chemistry, 1996, vol. 271. pp. 2506-2507.
Zaritsky et al., “Targeted Disruption of Kir2.1 and Kir2.2 Genes Reveals the Essential Role of the Inwardly Rectifying K+ Current in K+ Mediated Vasodilation” (2000) Circ. Res. 87:160-166.
Nuss HB et al. “Overexpression of a Human Potassium Channel Suppresses Cardiac Hyperexcitability in Rabbit Ventricular Myocytes” (1999) JCI 103(6):889-896.
Nuss HB et al., “Reversal of Potassium Channel Deficiency in Cells From Failing Hearts by Adenoviral Gene Transfer; A Prototype for Gen Therapy for Disorders of Cardiac Excitability and Contractility” (1996) Gene Therapy 3 (3):900-912.
Plaster et al., “Mutation in Kir 2.1 Cause the Developmental and Episodic Electrical Phenotypes of Anderson's Syndrome” (2001) Cell 105:511-519.
Plotinikov, AN, “Biological Pacemaker Implanted in Canine Left Bundle Branch Provides Ventricular Escape Rhythms That Have Physiologically Acceptable Rates” (2004) Circulation 109: 506-512.
Proenza et al., “Pacemaker Channels Produce and Instantaneous Current” (2002) JBC 277(7):5101-5109.
Rosen, MR et al., “Genes, Stem Cells and Biological Pacemakers” (2004) Cardiovasc. Res. V. 64(1):12-23.
Saffitz et al., “Mechanisms of Remodeling of Gap Junction Distributions and the Development of Anatomic Substrates of Arrhythmias” (1999) Cardiovasc Res. 42:309-317.
Schroder “Gene Delivery Approaches to Heart Failure Treatment” (2004) Expert Opin. Biol. Ther. 4(9):1413-1422.
Sehareseyon J et al., “Molecular Composition of Mitochondrial ATP-Sensitive Potassium Channels Probed by Viral Kir Gene Transfer” (2000) J. Mol. Cell. Cardiol. 32:1923-1930.
Sobey et al., “Knockout Blow for Channel Identity Crisis Vasodilation to Potassium is Mediated Via Kir2.1” (2000) Circ. Res. 87:83-84.
Sugiyama A et al., “Measurement of Adenylyl Cyclase Activity in the AV Nodal Region of the Canine Heart: Evidence for Inhibition by Adenosine and Acetylcholine” (1997) J. of Cardiovasc. Pharm. vol. 29, pp. 734-739.
Swifka et al., “Epicardial Fat From Guinea Pig: A Model to Study the Paracrine Network of Interactions Between Epicardial Fat and Myocardium?” (2008) Cardiovasc. Drugs and Ther. 22:107-114.
Tinker et al., “Regions Responsible for the Assembly of Inwardly Rectifying Potassium Channels” (1996) Cell 87:857-868.
Tiritilli, A., “DOCA-Salts Induce Heart Failure in the Guinea Pig” (2001) Eur. J. of Heart Fail. 3:545-551.
Tomaselli GF et al., “Electrophysiological Remodeling in Hypertrophy and Heart Failure” (1999) Cardiovascular Res. 42:270-283.
Weimann, JM et al, “Stable Reprogrammed Heterokaryons Form Spontaneously in Purkinje Neurons After Bone Marrow Transplant” (2003) Nature Cell Biol. 5(11):959-966.
Xue T et al., “Dominant-Negative Suppression of HCN-1 and HCN-2-Encoded Pacemaker Current by an Engineered HCN1 Construct (Insights Into Structure-Function Relationships and Mulitmerization)” (2002) Circ. Res. 90:1267-1273.
Xue T et al., “Functional Integration of Electrically Active Cardiac Derivatives From Genetically Engineered Human Embryonic Stem Cells With Quiescent Recipient Ventricular Cardiomyocytes” (2005) Circulation 111(1): 11-20.
Yamagishi T et al., “Molecular Architecture of the Voltage-Dependent NA Channel: Functional Evidence for Helicase in the Pore” (2001) J. Gen Phys. 118:171-181.
Yla-herttuala, “Cardiovascular Gene Therapy” (2000) Lancet 355:213-222.
Marban, “Cardiac Channelopathies”, Nature, Jan. 10, 2002, pp. 213-218, vol. 415.
Maguire et al., “Gem: An Induced, Immediate Early Protein Belonging to the Ras Family”, Science, Jul. 8, 1994, vol. 265.
Leone et al., “The Gem GTP-binding Protein Promotes Morphological Differentiation in Neuroblastoma”, Oncogene, pp. 3217-3225, vol. 20, 2001.
Neyroud et al., “Gene Delivery to Cardiac Muscle”, Methods in Enzymology, pp. 323-334, vol. 346, 2002.
Marban et al., “Gene Therapy for Cardiac Arrhythmias”, Cold Spri
Marban Eduardo
Murata Mitsushige
Banner & Witcoff , Ltd.
Montanari David
Paras, Jr. Peter
The John Hopkins University
LandOfFree
Focal calcium channel modulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Focal calcium channel modulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Focal calcium channel modulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710126